Grail continues facing significant challenges as its stock plummeted over 45% after its landmark NHS-Galleri trial failed to ...

The Primary Endpoint of Statistically Significant Combined Stage III-IV Reduction Was Not Met, However A Favorable Trend Was Observed Over Time GRAIL Announces U.S. Sales Force Expansion Based on ...

BIOPREVENT’ AI tool predicts transplant-related immune conflict and mortality risk using biomarkers, helping doctors ...

Sold More Than 185,000 Galleri® Tests in 2025, Growing U.S. Galleri Revenue 26% Year-Over-Year to $136.8 Million Completed Galleri PMA Submission to FDA Shared Topline ...

An international research team, with significant involvement from the Medical University of Vienna, has developed a new AI-based analysis method that can accurately classify brain tumors using genetic ...